Gabriela Jimborean

Prof. Dr. Gabriela Jimborean

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAlpár Csipor Fodor
Alpár Csipor Fodor
DHDragos Hutanu
Dragos Hutanu
CBCorina Eugenia Budin
Corina Eugenia Budin
MIMaria Beatrice Ianoși
Maria Beatrice Ianoși
DRDelia Liana Rachiș
Delia Liana Rachiș
GJGabriela Jimborean
Gabriela Jimborean
Central sleep apnea (CSA) is a heterogeneous group of sleep-related breathing disorders characterized by intermittent absence of respiratory effort during sleep. CSA results from impaired neurological signaling from the respiratory centers to the respiratory muscles, leading to airflow cessation for at least 10 s. Major causes include heart failure, opioid use, central neurological disorders, and altitude exposure. This review outlines the pathophysiology of CSA, emphasizing ventilatory instability and brainstem dysfunction as key mechanisms. It details the classification of CSA subtypes, including Cheyne–Stokes respiration, high-altitude CSA, and drug-induced CSA. Clinical manifestations range from excessive daytime sleepiness to cardiovascular complications. Diagnostic approaches encompass polygraphy, polysomnography, and various laboratory tests to evaluate comorbidities. Treatment requires a multidisciplinary approach, addressing underlying conditions while utilizing positive airway pressure (PAP) therapy, adaptive servo-ventilation (ASV), supplemental oxygen, and pharmacological interventions. Newer modalities, such as phrenic nerve stimulation, offer promising outcomes for CSA management. This review underscores the necessity of an individualized, interdisciplinary strategy to improve patient outcomes in CSA.

22 August 2025 in Diagnostics
Verified
Journal Article
Open access
MVMara Andreea Vultur
Mara Andreea Vultur
BGBianca Liana Grigorescu
Bianca Liana Grigorescu
DHDragos Hutanu
Dragos Hutanu
EDITH-SIMONA IANOSIEDITH-SIMONA IANOSI
EDITH-SIMONA IANOSI
CBCorina Eugenia Budin
Corina Eugenia Budin
GJGabriela Jimborean
Gabriela Jimborean
Obesity Hypoventilation Syndrome (OHS), also known as Pickwickian syndrome, is a complex disorder characterized by obesity (BMI > 30 kg/m2), daytime hypercapnia (PaCO2 ≥ 45 mmHg), and sleep-disordered breathing, primarily affecting individuals with severe obesity. Its diagnosis requires the exclusion of other causes of alveolar hypoventilation and involves comprehensive assessments, including clinical history, physical examination, pulmonary function tests, arterial blood gases, and sleep studies. The pathophysiology of OHS involves mechanical constraints from excessive adipose tissue, diminished central respiratory drive often linked to leptin resistance, mitochondrial dysfunction, and oxidative stress, all contributing to impaired ventilation and systemic inflammation. The condition often coexists with obstructive sleep apnea (OSA), exacerbating nocturnal hypoxia and hypercapnia, which can lead to severe cardiopulmonary complications such as pulmonary hypertension and right-sided heart failure. Epidemiologically, the rising global prevalence of obesity correlates with an increased incidence of OHS, yet underdiagnosis remains a significant challenge, often resulting in critical presentations like acute hypercapnic respiratory failure. Management primarily centers on non-invasive ventilation modalities like CPAP and BiPAP, with an emphasis on individualized treatment plans, continuous monitoring, and addressing comorbidities such as hypertension and diabetes. Pharmacological interventions are still evolving, focusing on supportive care and metabolic regulation. Long-term adherence, psychological factors, and complications like ventilator failure or device intolerance highlight the need for ongoing multidisciplinary management. Overall, advancing our understanding of OHS’s multifactorial mechanisms and optimizing tailored therapeutic strategies are crucial for improving patient outcomes and reducing mortality associated with this increasingly prevalent syndrome.

3 December 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
GJGabriela Jimborean
Gabriela Jimborean
EDITH-SIMONA IANOSIEDITH-SIMONA IANOSI
EDITH-SIMONA IANOSI
DHDragos Hutanu
Dragos Hutanu
HSHèdi Katalin Sárközi
Hèdi Katalin Sárközi
MVMara Andreea Vultur
Mara Andreea Vultur
ACAlpár Csipor-Fodor
Alpár Csipor-Fodor
Background: Tuberculosis remains one of the biggest global public health problems today. The objective of this study was to evaluate the diagnostic methods, clinical outcomes, patient compliance, and mortality rates in patients diagnosed with extrarespiratory tuberculosis. Methods: 105 cases of extrarespiratory tuberculosis were analyzed over a five-year period (2018–2023). Data from medical records were reviewed and processed. Diagnostic methods included Ziehl–Nielsen staining, Löwenstein–Jensen cultures, GeneXpert, and histopathological analysis. Diagnosis was supplemented by a specialist organ examination and, in cases with concurrent pulmonary involvement, by a chest X-ray and sputum examination. For negative cases, a probabilistic diagnosis was made. Results: Most patients presented pleural TB (38%), osteo-articular TB (26.67%), and ganglionary TB (19%). Patients were mostly men (56.19%), in the 18–40 years-old category (40%), and lived in rural areas (61%). In total, 94.29% were newly diagnosed and most observed comorbidites were chronic smoking (11.37%), chronic lung diseases (10.20%), and malnutrition (9.02%). Moreover, 68% had a negative microscopic examination, while 55% had negative cultures on Löwenstein–Jensen. Conclusions: This study highlights the importance of a multi-modal approach to diagnosing extrarespiratory tuberculosis, especially in negative bacteriological and histopathological results. Imaging, combined with clinical and epidemiological data, is critical for a probabilistic diagnosis. GeneXpert proved useful in difficult cases. This study emphasizes the need for a comprehensive diagnostic strategy to effectively manage extrarespiratory tuberculosis.

14 October 2023 in Romanian Journal of Rhinology
Verified
Journal Article
Open access
PDF file
GJGabriela Jimborean
Gabriela Jimborean
HSHedy Balogh Sarkozy
Hedy Balogh Sarkozy
MSMioara Szatmari
Mioara Szatmari
CNCristian Mircea Neagos
Cristian Mircea Neagos
AVAnca Vlad
Anca Vlad
ANAdriana Neagos
Adriana Neagos
BACKGROUND. Sleep-breathing disorders are increasingly common in the general population, affecting the quality of life from many points of view. Patients with sleep-disordered breathing have a series of comorbidities, including arterial hypertension, which affects the quality of life also through the collateral manifestations of daytime sleepiness. MATERIAL AND METHODS. A descriptive study was conducted on a group of 134 patients who underwent investigations to determine the degree of obstructive sleep apnea syndrome (OSAS) by respiratory polygraphic and polysomnographic investigations. This group was also investigated from the point of view of blood pressure values as well as the degree of daytime sleepiness, an important element for the quality of life. RESULTS. The average age of the evaluated patients was 42.18±12.70 years, and the body mass index was 31.20±5.74 kg/m 2 . The assessment of systemic blood pressure indicated an increased value above its standard normal value in most subjects: 58 patients (43.9%) were included in stage I hypertension, 9.8% in stage II, 1.5% of the subjects were diagnosed with stage III hypertension. To describe the relationship between OSAS and quality of life assessed by the degree of daytime sleepiness, we performed the regression and correlation analysis. The dependence between the values of the apnea-hypopnea index (AHI) and the ESS (the degree of daytime sleepiness) was positive; an increase in the AHI implies an increase in the ESS, thus a decrease in the quality of life. CONCLUSION. We can conclude that the severity of OSAS is directly involved in establishing the degree of arterial hypertension. Moreover, early detection is essential in order to decrease the degree of daytime sleepiness and implicitly increase the quality of life.

29 October 2024 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
EDITH-SIMONA IANOSIEDITH-SIMONA IANOSI
EDITH-SIMONA IANOSI
GZGall Zsuzsánna
Gall Zsuzsánna
DRDelia Rachiș
Delia Rachiș
DHDragos Hutanu
Dragos Hutanu
CBCorina Eugenia Budin
Corina Eugenia Budin
GJGabriela Jimborean
Gabriela Jimborean
Introduction: Chronic obstructive pulmonary disease (COPD) has a severe impact on patients’ health and can lead to multiple complications. Material and methods: We analyzed the co-occurrence of obstructive sleep apnea (OSA) in COPD patients hospitalized in the Pneumology Clinic of Târgu Mureș, Romania. Results: A total of 150 COPD patients were investigated by clinical examination, STOP-BANG and Epworth questionnaires, ventilatory polygraphy (PG), EKG, cardiac ultrasound, blood lipids, and sugar. Sixty-eight patients (45.3%) had OSA associated with COPD. A total of 61.7% were COPD gr. E, and 30.8% were gr. B. Frequently shown symptoms were snoring and nonrestorative sleep (100%), somnolence (73.5%), nocturnal awakenings (41.17%), morning headache (32.3%), and aggravated dyspnea. Types of OSA included obstructive (97.05%), central (2.5%), and associated obesity–hypoventilation (39.7%). A total of 76.4% were recently diagnosed with OSA. Men predominated at 70.5%, 76.4% were smokers, and 61.7% had experienced alcohol abuse. A total of 25% were overweight, and 71% had obesity. A total of 13.2% belonged to the category of 38–50-year-olds, 55.8% were in the 51–65-year-old category, 17.6% were in the 66–70-year-old category, and roughly 13.2% were in the 71-year-old category. Overlap syndrome (OS) comorbidities and complications were frequently present: 41% experienced respiratory failure, 66.1% experienced blood hypertension, 58.8% experienced ischemic cardiac disease, 32.35% experienced diabetes mellitus, 50% experienced dyslipidemia, and 29.4% experienced cor pulmonale. Conclusions: OS conferred gravity or directly contributed to cardiovascular, respiratory, and metabolic complications. OS was associated with more severe COPD and obesity. The prevalence of smoking in OS patients was higher than the national/European average.

16 July 2025 in Life
Verified
Journal Article
Open access
PDF file
CMCorina Mărginean
Corina Mărginean
DHDragos Hutanu
Dragos Hutanu
MVMara Andreea Vultur
Mara Andreea Vultur
HSHèdi Katalin Sárközi
Hèdi Katalin Sárközi
EDITH-SIMONA IANOSIEDITH-SIMONA IANOSI
EDITH-SIMONA IANOSI
CBCorina Eugenia Budin
Corina Eugenia Budin
Background: Severe asthma, which is characterized by persistent symptoms despite standard therapies, presents a significant clinical challenge. Biologic therapies targeting specific inflammatory pathways offer a potential avenue for achieving disease remission. This retrospective study evaluates the effectiveness of biologic therapies in achieving remission in severe asthma within a central Romanian cohort. Methods: Forty-eight patients with severe asthma treated with omalizumab, benralizumab, or dupilumab (2020–2025) were assessed. Clinical remission was defined using ACT scores, exacerbation frequency, corticosteroid use, and FEV1. Biological remission was determined using FeNO and eosinophil levels. Statistical analysis was performed to compare treatment outcomes. Results: At 12 months, 75% of patients achieved biological remission, and 75% reached clinical remission criteria. Significant improvements were observed in FEV1 (p < 0.001), eosinophil counts (p < 0.001), and ACT scores (p < 0.001). Complete remission, encompassing clinical, biological, and functional normalization, was observed in 54.2% of patients. Conclusion: Biologic therapies demonstrate promise in inducing comprehensive remission in severe asthma, supporting their role in improving disease control and lung function. Further research with larger cohorts is warranted.